In Vitro Susceptibility Tests in the Context of Antifungal Resistance: Beyond Minimum Inhibitory Concentration in Candida spp
- PMID: 38132789
- PMCID: PMC10744879
- DOI: 10.3390/jof9121188
In Vitro Susceptibility Tests in the Context of Antifungal Resistance: Beyond Minimum Inhibitory Concentration in Candida spp
Abstract
Antimicrobial resistance is a matter of rising concern, especially in fungal diseases. Multiple reports all over the world are highlighting a worrisome increase in azole- and echinocandin-resistance among fungal pathogens, especially in Candida species, as reported in the recently published fungal pathogens priority list made by WHO. Despite continuous efforts and advances in infection control, development of new antifungal molecules, and research on molecular mechanisms of antifungal resistance made by the scientific community, trends in invasive fungal diseases and associated antifungal resistance are on the rise, hindering therapeutic options and clinical cures. In this context, in vitro susceptibility testing aimed at evaluating minimum inhibitory concentrations, is still a milestone in the management of fungal diseases. However, such testing is not the only type at a microbiologist's disposal. There are other adjunctive in vitro tests aimed at evaluating fungicidal activity of antifungal molecules and also exploring tolerance to antifungals. This plethora of in vitro tests are still left behind and performed only for research purposes, but their role in the context of invasive fungal diseases associated with antifungal resistance might add resourceful information to the clinical management of patients. The aim of this review was therefore to revise and explore all other in vitro tests that could be potentially implemented in current clinical practice in resistant and difficult-to-treat cases.
Keywords: Candida spp. fungicidal tests; antifungal resistance; antifungal susceptibility testing; antifungal tolerance; minimum fungicidal concentration; serum fungicidal concentration; time-kill curve analysis.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10744879/bin/jof-09-01188-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10744879/bin/jof-09-01188-g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10744879/bin/jof-09-01188-g003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10744879/bin/jof-09-01188-g004.gif)
Similar articles
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.Dan Med J. 2016 Oct;63(10):B5288. Dan Med J. 2016. PMID: 27697142 Review.
-
Small molecules restore azole activity against drug-tolerant and drug-resistant Candida isolates.mBio. 2023 Aug 31;14(4):e0047923. doi: 10.1128/mbio.00479-23. Epub 2023 Jun 16. mBio. 2023. PMID: 37326546 Free PMC article.
-
Echinocandin antifungal drugs in fungal infections: a comparison.Drugs. 2011 Jan 1;71(1):11-41. doi: 10.2165/11585270-000000000-00000. Drugs. 2011. PMID: 21175238 Review.
-
Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment.Am J Med. 2012 Jan;125(1 Suppl):S3-13. doi: 10.1016/j.amjmed.2011.11.001. Am J Med. 2012. PMID: 22196207 Review.
References
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous